ArticleCellular oncology (Dordrecht, Netherlands)2025
The oncogenic potential of YAP requires Y357 phosphorylation in cholangiocytes but not in hepatocytes.
Article in Cellular oncology (Dordrecht, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeThe transcriptional cofactor yes-associated protein (YAP) is activated in primary liver cancers (PLCs). YAP is canonically inhibited through serine 127 (S127) phosphorylation via the Hippo pathway but activated by phosphorylation at tyrosine 357 (Y357) by SRC family kinases. Due to liver plasticity, PLCs can originate from different cell types. However, it is unknown whether YAP activation favors tumorigenesis from specific cells of origin or promotes lineage commitment during tumorigenesis. This study investigates how YAP Y357 phosphorylation influences tumor phenotype and cell of origin.
methodsC57BL/6 mice underwent biliary transfection with myr-AKT and YAP S127A (YAP-S) or YAP S127A/Y357F (YAP-SY). RNA sequencing and pathway analysis were performed on tumors. To determine the cell of origin, tumors were generated in lineage-tracing mice by biliary transfection or hydrodynamic tail vein injection. Two tumor-derived cell lines were isolated and characterized.
resultsYAP-S mice developed more frequent intrahepatic cholangiocarcinoma (iCCA), whereas a shift to hepatocellular carcinoma (HCC) was identified in YAP-SY mice. Transcriptome analysis revealed differential activation of pathways linked to this phenotypic switch. Lineage tracing demonstrated iCCA originated from cholangiocytes and HCC from hepatocytes in the biliary transfection, whereas iCCA originated from hepatocytes in the hydrodynamic tail vein injection. Two novel, transplantable syngeneic cell lines with mixed HCC/iCCA features were established. Tumors and cell lines commonly exhibited differential TGF-β signaling.
conclusionsYAP Y357 phosphorylation modifies the tumor phenotype and the cell of origin in liver cancer models. Differential TGF-β signaling suggests a potential therapeutic avenue for iCCA and mixed tumors. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.